← All trials
NCT00603304
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2008
- Primary completion
- Dec 1, 2010
- Completion date
- Dec 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 369
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Alabama, BirminghamLead sponsor
- Washington University in St. LouisCollaborator
- Harvard UniversityStudy chair
- National Center for Complementary and Integrative Health (NCCIH)Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- Cornell UniversityCollaborator
- New York UniversityCollaborator
- Kaiser PermanenteCollaborator
- Northwestern UniversityCollaborator
- University of Colorado, DenverCollaborator
- University of IowaCollaborator
- University of MarylandCollaborator
- Yale UniversityCollaborator
- Office of Dietary Supplements (ODS)Collaborator
- Queen's University, BelfastCollaborator
- University of Alabama, BirminghamOverall official - principal investigator
- University of Alabama, BirminghamReponsible party - principal investigator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.